Evolution of pneumococcal serotype epidemiology in Botswana following introduction of 13-valent pneumococcal conjugate vaccine

被引:5
|
作者
Patel, Sweta M. [1 ,2 ]
Shaik-Dasthagirisaheb, Yazdani B. [3 ]
Congdon, Morgan [4 ]
Young, Rebecca R. [5 ]
Patel, Mohamed Z. [6 ]
Mazhani, Tiny [6 ]
Boiditswe, Sefelani [7 ]
Leburu, Tirayaone [7 ]
Lechiile, Kwana [7 ]
Arscott-Mills, Tonya [4 ,6 ,7 ]
Steenhoff, Andrew P. [4 ,6 ,8 ,9 ]
Feemster, Kristen A. [8 ,9 ]
Shah, Samir S. [10 ,11 ]
Cunningham, Coleen K. [12 ]
Pelton, Stephen I. [3 ]
Kelly, Matthew S. [2 ,5 ]
机构
[1] Duke Univ, Div Pulm Allergy & Crit Care Med, Durham, NC 27708 USA
[2] Duke Univ, Duke Global Hlth Inst, Durham, NC 27708 USA
[3] Boston Univ, Sch Med, Div Pediat Infect Dis, Boston, MA 02118 USA
[4] Childrens Hosp Philadelphia, Div Gen Pediat, Philadelphia, PA 19104 USA
[5] Duke Univ, Div Pediat Infect Dis, Durham, NC USA
[6] Univ Botswana, Fac Med, Dept Paediat & Adolescent Hlth, Gaborone, Botswana
[7] Botswana Univ Pennsylvania Partnership, Gaborone, Botswana
[8] Childrens Hosp Philadelphia, Div Pediat Infect Dis, Philadelphia, PA USA
[9] Childrens Hosp Philadelphia, Dept Pediat, Global Hlth Ctr, Philadelphia, PA 19104 USA
[10] Cincinnati Childrens Med Ctr, Div Hosp Med, Cincinnati, OH USA
[11] Cincinnati Childrens Med Ctr, Div Infect Dis, Cincinnati, OH USA
[12] Univ Calif Irvine, Dept Pediat, Irvine, CA 92717 USA
来源
PLOS ONE | 2022年 / 17卷 / 01期
基金
美国国家卫生研究院;
关键词
CARRIAGE; CHILDREN;
D O I
10.1371/journal.pone.0262225
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Pneumococcal conjugate vaccines reduce the burden of invasive pneumococcal disease, but the sustained effect of these vaccines can be diminished by an increase in disease caused by non-vaccine serotypes. To describe pneumococcal serotype epidemiology in Botswana following introduction of 13-valent pneumococcal conjugate vaccine (PCV-13) in July 2012, we performed molecular serotyping of 268 pneumococcal strains isolated from 221 children between 2012 and 2017. The median (interquartile range) age of the children included in this analysis was 6 (3,12) months. Fifty-nine percent of the children had received at least one dose of PCV-13 and 35% were fully vaccinated with PCV-13. While colonization by vaccine serotypes steadily declined following PCV-13 introduction, 25% of strains isolated more than 3 years after vaccine introduction were PCV-13 serotypes. We also observed an increase in colonization by non-vaccine serotypes 21 and 23B, which have been associated with invasive pneumococcal disease and antibiotic resistance in other settings.
引用
下载
收藏
页数:9
相关论文
共 50 条
  • [31] Kawasaki Disease Following the 13-valent Pneumococcal Conjugate Vaccine and Rotavirus Vaccines
    Kamidani, Satoshi
    Panagiotakopoulos, Lakshmi
    Licata, Charles
    Daley, Matthew F.
    Yih, W. Katherine
    Zerbo, Ousseny
    Tseng, Hung Fu
    DeSilva, Malini B.
    Nelson, Jennifer C.
    Groom, Holly C.
    Williams, Joshua T. B.
    Hambidge, Simon J.
    Donahue, James G.
    Belay, Ermias D.
    Weintraub, Eric S.
    PEDIATRICS, 2022, 150 (06)
  • [32] Surveillance of adverse events following the introduction of 13-valent pneumococcal conjugate vaccine in infants, and comparison with adverse events following 7-valent pneumococcal conjugate vaccine, in Victoria, Australia
    Littlejohn, E. S.
    Clothier, H. J.
    Perrett, K. P.
    Danchin, M.
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2015, 11 (07) : 1828 - 1835
  • [33] The Effect of 13-Valent Pneumococcal Conjugate Vaccine on the Serotype Distribution and Antibiotic Resistance Profiles in Children With Invasive Pneumococcal Disease
    Gaviria-Agudelo, Claudia L.
    Jordan-Villegas, Alejandro
    Garcia, Carla
    McCracken, George H., Jr.
    JOURNAL OF THE PEDIATRIC INFECTIOUS DISEASES SOCIETY, 2017, 6 (03) : 253 - 259
  • [34] Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in Mexico
    Gutierrez Brito, Maricruz
    Thompson, Allison
    Girgenti, Douglas
    Giardina, Peter C.
    Sarkozy, Denise A.
    Gruber, William C.
    Emini, Emilio A.
    Scott, Daniel A.
    REVISTA PANAMERICANA DE SALUD PUBLICA-PAN AMERICAN JOURNAL OF PUBLIC HEALTH, 2013, 33 (06): : 414 - 421
  • [35] Effectiveness of the new serotypes in the 13-valent pneumococcal conjugate vaccine
    Miller, Elizabeth
    Andrews, Nicholas J.
    Waight, Pauline A.
    Slack, Mary P. E.
    George, Robert C.
    VACCINE, 2011, 29 (49) : 9127 - 9131
  • [36] Efficacy of 13-valent pneumococcal conjugate vaccine in healthcare workers
    Shpagina, L. A.
    Kotova, O. S.
    Shpagin, I. S.
    Loktin, E. M.
    Rukavitsyna, A. A.
    Kuznetsova, G., V
    Kamneva, N., V
    Laletina, M. A.
    TERAPEVTICHESKII ARKHIV, 2018, 90 (11): : 55 - 61
  • [37] Pneumococcal Polysaccharide Conjugate Vaccine (13-Valent, Adsorbed) [Prevenar 13®]
    Duggan, Sean T.
    DRUGS, 2010, 70 (15) : 1973 - 1986
  • [38] Pneumococcal Conjugate Vaccine-elicited Antibody Persistence and Immunogenicity and Safety of 13-Valent Pneumococcal Conjugate Vaccine in Children Previously Vaccinated with 4 Doses of Either 7-Valent or 13-Valent Pneumococcal Conjugate Vaccine
    Quinet, Beatrice
    Laudat, France
    Gurtman, Alejandra
    Patterson, Scott
    Sidhu, Mohinder
    Gruber, William C.
    Scott, Daniel A.
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2014, 33 (10) : 1065 - 1076
  • [39] Advances in Pneumococcal Disease Prevention: 13-Valent Pneumococcal Conjugate Vaccine for Infants and Children
    Paradiso, Peter R.
    CLINICAL INFECTIOUS DISEASES, 2011, 52 (10) : 1241 - 1247
  • [40] Occult bacteremia etiology following the introduction of 13-valent pneumococcal conjugate vaccine: a multicenter study in Spain
    Susanna Hernández-Bou
    Borja Gómez
    Santiago Mintegi
    Juan J. García-García
    European Journal of Clinical Microbiology & Infectious Diseases, 2018, 37 : 1449 - 1455